



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Sucrostate potassium

Cat. No.:	HY-141436
CAS No.:	73264-44-5
Molecular Formula:	C <sub>12</sub> H <sub>14</sub> K <sub>8</sub> O <sub>35</sub> S <sub>8</sub>
Molecular Weight:	1287.52
Target:	Biochemical Assay Reagents
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Sucrostate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrostate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398<sup>[1][2]</sup>.

### REFERENCES

- [1]. Ko A H, Tempero M A, Shan Y S, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrostate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer[J]. British journal of cancer, 2013, 109(4): 920-925.
- [2]. Klinz S G, Zheng J, De Souza R, et al. Abstract C293: Irinotecan sucrostate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F] FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model[J]. Molecular Cancer Therapeutics, 2013, 12(11\_Supplement): C293-C293.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA